Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction

Area of Science:

• Oncology
• Vascular Biology
• Biotechnology

Background:

• Tissue Factor (TF) plays a role in malignancy development.
• Targeting TF's truncated extracellular part (tTF) to tumor vasculature is a potential cancer therapy.
• This approach aims to induce tumor vessel occlusion and infarction.

Purpose of the Study:

• To explore retargeting tTF to tumor vasculature for cancer treatment.
• To identify and evaluate various molecular targets on tumor vascular cells for tTF delivery.
• To assess the clinical efficacy of tTF-based cancer therapies.

Main Methods:

• Utilizing antibodies, derivatives, or bifunctional fusion proteins to direct tTF to tumor targets.
• Investigating multiple targets including adhesion molecules, growth factor receptors, and cell surface proteins like aminopeptidase N.
• Developing tTF-NGR as a drug candidate targeting aminopeptidase N on angiogenic endothelial cells.

Main Results:

• Multiple molecular targets on tumor vascular cells have been identified for tTF delivery.
• tTF-NGR emerged as the first coaguligand drug candidate to enter clinical studies.
• tTF-NGR has progressed to randomized oncology studies for therapeutic evaluation.

Conclusions:

• Retargeting tTF to tumor vasculature represents a novel therapeutic strategy in oncology.
• tTF-NGR demonstrates promise as a coaguligand-based cancer therapeutic.
• Further clinical studies are necessary to confirm the therapeutic impact of tTF-NGR.